Vardenafil, a potent and selective phosphodiesterase 5 inhibitor, has entered phase 3 clinical trials. Pharmacodynamic studies showed that the maximum plasma concentration after oral administration of 20 -40 mg of vardenafil occurred in 0.7 -0.9 h, the half-life was 4 -5 h, and negligible amounts remained in the circulation after 24 h. The efficacy of vardenafil compared with placebo was shown in RigiScan studies, a phase 2 study involving 601 men with mild-tosevere erectile dysfunction for at least 6 months, and a phase 3 study involving 452 diabetic men. Adverse effects were not severe and tended to decrease with time.
Introduction
Cyclic guanosine monophosphate (cGMP) is the second messenger released by nitric oxide in the cascade of events that brings about erection by the relaxation of smooth muscle in the corpus cavernosum. The catabolism of cGMP by phosphodiesterase isotype 5 (PDE-5) can be inhibited by PDE-5 inhibitors, and this action has been used to treat erectile dysfunction. Vardenafil is a new PDE-5 inhibitor that has high potency in vitro (50% inhibitory concentration, 0.6 nM) and selectivity for PDE-5 compared with other isoenzymes. 1 It has been shown to be active for inducing penile erection in a conscious rabbit model when given orally. 2, 3 This article reviews the available clinical data on vardenafil.
Initial pharmacokinetic and efficacy studies
Pharmacokinetic data were obtained in two randomized, double-blind, placebo-controlled 3-fold crossover studies with a single oral dose of 10, 20, or 40 mg of vardenafil. These studies were performed to assess the effect of the drug during RigiScan studies in 42 men who had had mild-tomoderate erectile dysfunction for more than 6 months. 4, 5 The studies were performed in two centers with different dosing schedules. These results showed that the time to maximum plasma concentration of vardenafil was 0.7 -0.9 h. This number decreased to half in 4 -5 h and was unrecordable after all doses by 24 h.
The efficacy of vardenafil was assessed in these studies by the measurement of RigiScan data during three 20-min periods of visual sexual stimuli commencing 20 min after oral placebo or vardenafil administration. The primary end point was the duration of rigidity at the tip and the base of the penis of more than 60%, and secondary end points were rigidity and tumescence at the base and the tip of the penis as calculated by the RigiScan device. Figure 1 shows that there was a significant difference in rigidity at the base of the penis between placebo and vardenafil at all doses, but there was no significant difference between 20 and 40 mg of vardenafil. Figure 2 shows that the duration of rigidity greater than 60% at the base of the penis increased from 25 min to just more than 60 min with 40 mg of vardenafil. There was a significant difference between vardenafil and placebo at all doses, but again there was no significant difference between the 20-and 40-mg doses of vardenafil. Similar findings were recorded at the tip of the penis. (J Porst, unpublished data). 6 The men, aged 27 -70 y, were studied during a 4-week, unmedicated run-in period. The men then took placebo or 5, 10, or 20 mg of vardenafil on demand, but not more than once a day, at least 1 h before they intended to have sexual intercourse. They were forbidden to take nitrate medications or other treatment for their erectile dysfunction. All the men were in a stable heterosexual relationship, had had erectile dysfunction for more than 6 months, and had made at least four attempts at sexual intercourse during the run-in phase. Men with diabetes mellitus, hypogonadotrophism, spinal cord injury, a past prostatectomy, or clinically significant heart disease were excluded. A diary questionnaire was completed after every event, and efficacy was assessed using the International Index of Erectile Function (IIEF), 7 the FuglMeyer Quality of Life Questionnaire, 8 and the Global Assessment Question of 'Has the treatment you have been taking over the past 4 weeks improved your erections, yes or no?'
Phase 2b clinical trials of vardenafil in erectile dysfunction
The mean age of the 601 patients was 52 y, and the average duration of erectile dysfunction was 3 y. A similar mix of patients with regard to origin and severity of disease was found in all groups.
Efficacy, as assessed by IIEF question 3, increased from 2.5=2.6 at the outset to 2.7 in the placebo group and to 3.7, 3.6, and 4.0 in the 5-, 10-, and 20-mg doses of vardenafil groups, respectively (Figure 4 ). This increase was significant (P < 0.001) in all the vardenafil groups but not in the placebo group. Similarly, the baseline efficacy of 2.0=2.1 in question 4 increased significantly (P < 0.001) to 3.5, 3.6, and 3.8 with escalating doses of vardenafil compared with a small increase with placebo ( Figure 5 ). The Erectile Function Domain score was 14 at the start of the treatment, increased to 16 with placebo, and was 20 to 22 with vardenafil ( Figure 6) .
Examination of the diaries showed that 70.9 -74.6% of attempts at sexual intercourse were successful in the treated group compared with 39.5% in the placebo group and 23.7 -28.9% in the pretreatment phase. In response to the Global Assessment Question, it was found that 66 -80% of the vardenafil-treated men noted an improvement in contrast to only 30% in the placebo group (P < 0.001).
The efficacy of vardenafil was not affected by the age of the men or the severity or origin of the erectile dysfunction (J Porst, unpublished data). The effectiveness of the vardenafil was maintained throughout the 12-week study period. 9 Adverse effects were not troublesome (Table 1) . Flushing was the most frequently observed side effect and was observed in 10.2 -11.3% of treated men. The incidence of headache increased from 6.8% for those taking 5 mg of vardenafil to 15.3% with 20 mg of vardenafil. The incidence of headaches and other adverse effects tended to decrease during the 12-week period. 9 
Phase 3 studies
The first phase 3 study was performed in 452 diabetic men (88.9% had type 2 diabetes) older than 18 y and was reported at the 61st Annual American Diabetic Association Scientific Meeting in June 2001. 10 This was a 12-week, randomized, double-blind, placebo-controlled, multicenter study of men with mild-to-severe erectile dysfunction. The men were randomized to receive placebo (143) or 10-mg (152) or 20-mg (144) vardenafil tablets on demand but not more than once a day. Men with significant cardiac events during the preceding 6 months were excluded. The three groups were all well matched with regard to age (mean ages, 56.8, 58.0, and 56.9 y), racial origin, body mass index, duration of erectile dysfunction (3.7, 3.4, and 3.3 y, respectively), disease origin, and baseline IIEF scores (11, 10.8, and 12.0).
In response to the Global Assessment Question of 'Has the treatment you have been taking over the past 4 weeks improved your erections?' an improvement was noted in 13% with placebo, 57% with 10 mg of vardenafil, and 72% with 20 mg of vardenafil. The 10-and 20-mg vardenafil tablets significantly (P < 0.0001) improved the IIEF Erectile Function Domain scores (Figure 7) , the ability to penetrate, and maintenance of erection to intercourse completion.
The adverse effects of headaches, flushing, and rhinitis were similar to those found in other studies. Serious adverse events were rare (1.4%, 2.0%, and 2.8%, respectively), and these led to premature discontinuation of treatment of 1% with those taking placebo and 3% and 4% of men taking 10-and 20-mg tablets of vardenafil.
Discussion
The efficacy and safety of vardenafil in these shortterm studies have been demonstrated. Its efficacy in the initial phase 3 studies in diabetic men with relatively severe erectile dysfunction (IIEF Erectile Figure 6 Vardenafil phase 2 study: efficacy with regard to Erectile Function Domain score. 
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Function Domain score of 10 -12 compared with that of 14 in the phase 2b study) was surprisingly strong. It will be interesting to see how effective the drug is in the general population of men with erectile dysfunction and how well it performs when compared with sildenafil and tadalafil.
